|
Novartis expands alliance with Science 37 to advance virtual clinical trials program
|
09 March 2018 |
|
Novartis' Xolair® recommended in new global chronic urticaria guideline
|
06 March 2018 |
|
Novartis and Pear Therapeutics to develop digital therapeutics for patients with schizophrenia and multiple sclerosis
|
01 March 2018 |
|
Treatment with Novartis' Ultibro® Breezhaler® improved cardiac function in COPD patients with lung hyperinflation
|
22 February 2018 |
|
Novartis forms alliance to develop medicines for treating infectious diarrheal disease
|
16 February 2018 |
|
Advanced Accelerator Applications receives FDA approval for Lutathera® for treatment of gastroenteropancreatic neuroendocrine tumors
|
29 January 2018 |
|
Novartis reports erenumab met all primary and secondary endpoints in unique Phase IIIb study in episodic migraine patients who have failed multiple prior preventive treatments
|
22 January 2018 |
|
Sandoz announces exclusive global collaboration with Biocon on next-generation biosimilars
|
18 January 2018 |
|
Sandoz regulatory submission for proposed biosimilar adalimumab accepted by FDA
|
16 January 2018 |
|
Novartis appoints Elizabeth Barrett as Oncology Head
|
11 January 2018 |